FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number:	3235-0104							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						,						
1. Name and Address of Reporting Person*  Zanganeh Maky  2. Date of Event Requiring Statement (Month/Day/Year) 02/09/2017			nent	3. Issuer Name and Ticker or Trading Symbol Pulse Biosciences, Inc. [ PLSE ]								
(Last)	(First)	(Middle)	_			tionship of Reporting Person all applicable) Director	son(s) to Issuer		5. If Amendment, Date of Original Filed (Month/Day/Year)			
849 MITTEN ROAD, SUITE 104  (Street)  BURLINGAME CA 90401		TIE 104			24	Officer (give title below)	Other (sp		6. Individual or Joint/Group Filing (Check Applicable Line)			
		90401				,	,		X Form filed by One Reporting Person  Form filed by More than One Reporting Person			
(City)	(State)	(Zip)								-13		
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					ally Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock						258,935	258,935 D					
Common Stock						20,474	I			By son.		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)  2. Date Exercisable Expiration Date (Month/Day/Year)  Date Expiration Date Expiration Date Date Expiration Date Expiration Date Expiration Date Expiration Date Expiration Date		ate	and 3. Title and Amount of Secu Underlying Derivative Secu		rity (Instr. 4) Conve		ersion ercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
				Expiration Date	Title		Amount or Number of Shares	Price Deriva Secur	ative	Direct (D) or Indirect (I) (Instr. 5)		

**Explanation of Responses:** 

Remarks:

Maky Zanganeh

02/13/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

## POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of PULSE BIOSCIENCES, INC. (the "Company"), hereby constitutes and appoints Darrin R. Uecker and Brian B. Dow, and each of them, the undersigned's true and lawful attorney-in-fact, to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- 2. do all acts necessary in order to file such forms with the U.S. Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 10th day of February, 2017.

Mahkem Zanganeh Signature: /s/ Mahkem Zanganeh